HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS REGISTER		Author Keyword(s) Vol Page [Advanced]

This Article Full Text Full Text (PDF) Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Services Email this link to a friend Similar articles in this journal Similar articles in PubMed Add article to my folders Download to citation manager Request Permissions Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Snow, B Search for Related Content PubMed PubMed Citation Articles by Snow, B Related Collections Quality of life and health status Other Neurology Regulation Motor neurone disease Health care reforms: UK Related Article

Objective measures for the progression of Parkinson’s disease

Auckland Hospital, New Zealand;
bsnow@adhb.govt.nz

Keywords: Parkinson’s disease; SPECT; PET

The first 150 words of the full text of this article appear below.

A persisting frustration in the diagnosis, treatment, and research of Parkinson’s disease is the lack of an objective measure of the nigrostriatal dopaminergic deficit. In particular, we need a tool to monitor the progress of the neuronal degeneration. This is very difficult to achieve clinically in Parkinson’s disease because of the complex clinical presentation and the confounding effect of symptomatic therapy. Although PET, with markers of presynaptic dopaminergic function such as 6-fluorodopa, is an accepted measuring tool, PET is complex, expensive, cumbersome, and not widely available. The alternative is SPECT, and Winogrodzka et al on pp 294–298¹ of this issue provide evidence that SPECT does the job.

Winogrodzka et al took 50 patients with Parkinson’s disease and performed SPECT scans 12 months apart. For their tracer, they chose [¹²³I] ß-CIT, which binds to the presynaptic dopamine transporters. They showed an 8% decline in binding density. This matches . . . [Full text of this article]

Related Article

[¹²³I]ß-CIT SPECT is a useful method for monitoring dopaminergic degeneration in early stage Parkinson’s disease

A Winogrodzka, P Bergmans, J Booij, E A van Royen, J C Stoof, and E C Wolters
J. Neurol. Neurosurg. Psychiatry 2003 74: 294-298. [Abstract] [Full Text] [PDF]